1
Clinical Trials associated with GW-181771Effect of a CCK-1R Agonist on Food Intake in Humans
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.
100 Clinical Results associated with GW-181771
100 Translational Medicine associated with GW-181771
100 Patents (Medical) associated with GW-181771
1
Literatures (Medical) associated with GW-18177101 Jan 2005·Folia Pharmacologica Japonica
医薬品開発における放射性薬剤の利用:極微量(microdose)投与後の薬物動態のAMSおよびPETによる評価
Article
Author: 上原 知也 ; 荒野 泰
100 Deals associated with GW-181771